AZ launches Crestor co-pay card to battle Lipitor copies

Joining the growing number of drugmakers using discount cards and coupons to retain patients, AstraZeneca ($AZN) has launched a co-pay help card for its statin drug Crestor. The cholesterol remedy isn't on the verge of going off patent, as some other meds with co-pay cards are, but Lipitor, one of its biggest rivals, is.

The new card gives insured patients an $18 co-pay for Crestor, up to $50 off their current co-pays. A patient with a $75 co-pay would pay $25 with the card, for instance, while a patient with a $60 co-pay would pay $18. Uninsured patients get a $50 discount on each monthly supply for 12 months.

The Crestor discount isn't as big as Pfizer's ($PFE) new discounts on Lipitor, which give insured patients a $4 co-pay, but Crestor isn't battling directly against pharmacies touting co-pays of $4 for patients who switch to generic copies. On the other hand, Crestor may be viewed as a statin for harder-to-treat patients, but recent study data didn't show a statistically significant superiority to Lipitor as AstraZeneca had hoped. You can be sure that analysts will be keeping a close eye on prescription numbers as soon as Lipitor loses exclusivity Nov. 30.

- read the AstraZeneca release
- get more from PharmaLetter

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.